第一条 为加强公司定期报告及重大事项在编制、审议和披露期间对外信息报送和 使用管理，蓝帆医疗股份有限公司（以下简称"公司"）依据《中华人民共和国公司 法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》《上市公司信息披 露管理办法》等法律法规及《蓝帆医疗股份有限公司章程》《蓝帆医疗股份有限公司 信息披露事务管理制度》的规定，制定本办法。 第二条 本办法适用公司董事、高级管理人员及其他相关涉密人员，以及接受报送 的外部单位和个人。 外部信息报送和使用管理办法 第一章 总则 第三条 本制度所指信息包括但不限于定期报告、临时报告、财务数据、正在筹划 的重大事项等。 第四条 董事会秘书是公司对外报送信息工作的监管人，证券管理部协助董事会秘 书做好对外报送信息的日常管理工作。 第二章 外部信息报送细则 第十条 接受报送的外部单位或个人及其工作人员因保密不当致使前述重大信息 被泄露，应立即通知公司，公司要在第一时间向中国证监会、深圳证券交易所报告并 公告。 第三章 责任追究及责罚 第十一条 接受报送的外部单位或个人，如违反本办法的相关规定使用公司报送的 信息，致使公司遭受经济损失的，公司将依法要求其承担赔偿责任；外 ...

蓝帆医疗公告，2025年上半年营业收入27.81亿元，同比下降7.49%。净亏损1.35亿元，上年同期净亏损 1.6亿元。 ...

蓝帆医疗股份有限公司 2025 年半年度报告全文 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市临淄区稷下街道一诺路 48 号） 蓝帆医疗股份有限公司 二〇二五年半年度报告 股票代码：002382 $$\Xi{\bf{\mathrm{O}}}\,{\bf{\mathrm{=}}}\,\Xi{\bf{\mathrm{H}}}\,\rlap{\backslash}\,\Xi{\bf{\mathrm{H}}}$$ 1 蓝帆医疗股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责 任。 公司负责人刘文静、主管会计工作负责人崔运涛及会计机构负责人(会计 主管人员)崔运涛声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告中涉及未来的计划、经营目标等方面的内容，均不构成本公 司对任何投资者的实质承诺，投资者及相关人士均应对此保持足够的风险认 识，并且应当理解计划与承诺之间的差异，敬请广大 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-069 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于公司为子公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2024年12月6日召开了第六届董事 会第十六次会议、2024年12月23日召开了2024年第三次临时股东大会，审议并通过了 《关于2025年度公司及子公司申请授信及担保额度预计的议案》，公司及子公司2025 年度拟向银行等金融机构申请综合授信总额不超过人民币17.10亿元，授信品种包括但 不限于流动资金贷款、保函、银行承兑汇票、国内信用证、国内保理、融资租赁等综 合授信业务（具体业务品种以相关金融机构审批为准），具体融资金额将视公司及子 公司生产运营对资金的需求来确定。公司及子公司将根据金融机构的授信要求为上述 综合授信提供担保额度总计不超过人民币17.10亿元，其中，预计为公司及资产负债率 70 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-068 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 5、截至 2025 年 8 月 28 日，蓝帆医疗股份有限公司（以下简称"公司"）股票已 有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发"蓝帆转债"转股价格向 下修正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股 价格，并及时履行信息披露义务。 一、可转债发行上市基本情况 （一）可转债发行情况 关于预计触发可转债转股价格向下修正条件 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 11.50 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 2 ...

Group 1 - The core point of the news is that 蓝帆医疗 (Blue Sail Medical) has seen a steady increase in financing buy-in amounts over the recent trading days, indicating growing investor interest [1] - On August 25, 蓝帆医疗 had a financing buy-in amount of 0.30 billion yuan, ranking 2147th in the market, with a financing repayment amount of 0.25 billion yuan, resulting in a net buy of 5.5648 million yuan [1] - Over the last three trading days (August 21-25), 蓝帆医疗 recorded financing buy-ins of 0.19 billion yuan, 0.26 billion yuan, and 0.30 billion yuan respectively, showing a consistent upward trend [1] Group 2 - In terms of securities lending, on the same day, 蓝帆医疗 had a securities lending sell-out of 0.03 thousand shares and a net buy of 0.05 thousand shares [2]

Core Viewpoint - Bluefan Medical (002382) shows a mixed performance in stock price and fund flow, with a slight increase in stock price but significant net outflows from major funds [1][2]. Fund Flow Summary - On August 25, 2025, Bluefan Medical's stock closed at 6.52 CNY, up 1.4%, with a turnover rate of 3.14% and a trading volume of 314,300 hands, resulting in a transaction amount of 204 million CNY [1]. - The fund flow data indicates a net outflow of 10.38 million CNY from major funds, accounting for 5.09% of the total transaction amount, while retail funds saw a net inflow of 14.35 million CNY, representing 7.04% of the total [1][2]. - Over the past five days, the stock experienced fluctuations in fund flows, with notable net inflows and outflows from different investor categories [2]. Company Performance Metrics - As of the latest report, Bluefan Medical has a total market value of 6.566 billion CNY, with a net asset value of 10.102 billion CNY, and a net profit of 77.0223 million CNY [3]. - The company’s price-to-earnings ratio (P/E) stands at 21.31, significantly lower than the industry average of 75.1, while the price-to-book ratio (P/B) is 0.81, compared to the industry average of 4.05 [3]. - The gross margin is reported at 17.17%, which is considerably lower than the industry average of 51.32%, and the net profit margin is 5.58%, below the industry average of 10.74% [3]. - In the first quarter of 2025, Bluefan Medical reported a main business revenue of 1.478 billion CNY, a year-on-year increase of 1.59%, and a net profit attributable to shareholders of 77.0223 million CNY, a significant year-on-year increase of 177.86% [3].

Core Viewpoint - As of August 22, 2025, BluFan Medical (002382) closed at 6.43 yuan, down 0.92%, with a trading volume of 289,400 hands and a transaction amount of 186 million yuan [1] Group 1: Stock Performance and Trading Data - On August 22, 2025, the net inflow of main funds was 809,000 yuan, accounting for 0.44% of the total transaction amount, while retail investors had a net outflow of 6.5073 million yuan, accounting for 3.5% of the total transaction amount [1] - Over the past five days, the stock has experienced fluctuations in trading volume and price, with notable changes in net inflows and outflows from different investor categories [1] Group 2: Company Financial Metrics and Industry Comparison - BluFan Medical's total market value is 6.476 billion yuan, with a net asset of 10.102 billion yuan, and a net profit of 77.0223 million yuan, ranking 57th, 7th, and 32nd respectively in the medical device industry [2] - The company reported a revenue of 1.478 billion yuan for Q1 2025, a year-on-year increase of 1.59%, while the net profit increased by 177.86% [2] - The company's financial ratios include a price-to-earnings ratio of 21.02, a price-to-book ratio of 0.8, and a gross margin of 17.17%, which are significantly lower than the industry averages [2]

Group 1 - The core point of the news is that 蓝帆医疗 (Blue Sail Medical) has seen an increase in financing buy-in amounts over the recent trading days, indicating growing investor interest [1] - On August 20, Blue Sail Medical had a financing buy-in amount of 0.52 billion yuan, ranking 1165th in the market, with a financing repayment amount of 0.26 billion yuan, resulting in a net buy-in of 26.77 million yuan [1] - Over the last three trading days from August 15 to August 20, the financing buy-in amounts were 0.10 billion yuan, 0.22 billion yuan, and 0.52 billion yuan respectively, showing a positive trend [1] Group 2 - In terms of securities lending, on the same day, the company had a securities lending sell-out of 3000 shares, resulting in a net sell-out of 3000 shares [2]

Core Viewpoint - The research activity in the field of biomedical materials in China has been declining from 2014 to 2024, with a decrease in the number of related papers published from 258 to 152 [3]. Group 1: Definition and Overview - Biomedical materials are defined as high-tech materials used for diagnosing, treating, repairing, or replacing human tissues and organs, categorized by their applications such as bone, soft tissue, cardiovascular, and medical membrane materials [1]. Group 2: Research Trends - The number of papers published in the biomedical materials field has shown a downward trend, indicating a decrease in research interest over the years [3]. - As of July 2025, higher education institutions are the primary contributors to the literature in this field, with Tianjin University leading by publishing 102 related papers [5]. Group 3: Research Themes - Medical polymer materials are identified as a popular research theme within the biomedical materials sector, alongside composite materials [9]. - Biomedical engineering is recognized as a prominent research discipline in this field, with significant contributions from organic chemistry, metallurgy, and metal processing [11].